22:00 , Jul 11, 2019 |  BC Innovations  |  Product Development

How Zymeworks aims to take on Roche’s $10B HER2 franchise

Zymeworks is going head to head with one of the biggest commercial cancer franchises -- Roche’s Herceptin trastuzumab and Perjeta pertuzumab -- as it pursues clinical proof-of-concept for its protein engineering platform. Pivotal readouts in...
23:29 , Jul 10, 2019 |  BC Extra  |  Company News

How patient data will drive Clover Health’s new R&D unit

Health insurer Clover Health launched a drug discovery subsidiary Wednesday that has partnered with Genentech Inc. to leverage patient-derived data to identify age-related disease treatments. Through its R&D partnership with Genentech, Clover plans to focus...
19:14 , May 20, 2019 |  BC Extra  |  Clinical News

May 20 Clinical Quick Takes: Keytruda misses in TNBC; plus Medicines Co., Acadia, Takeda, Ocular

Keytruda fails in previously treated TNBC  Monotherapy with PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) missed the primary endpoint of improving overall survival vs. physician’s choice of single agent chemotherapy in the...
23:17 , May 10, 2019 |  BioCentury  |  Politics, Policy & Law

The unsung public policy innovators paving the path to cures

Patients with diseases like hemophilia, spinal muscular atrophy and β-thalassemia that could be cured with gene or cell therapies probably don’t know it, but their fates depend as much on the success of public policy...
22:48 , Apr 16, 2019 |  BC Extra  |  Company News

Flagship's Kintai debuts with small molecule microbiome mimic platform, CEO Tak

Kintai Therapeutics Inc. (Cambridge, Mass.) emerged from stealth mode Tuesday, defining Flagship Pioneering's fourth angle on microbiome-based therapeutics. The biotech's orally bioavailable small molecules mimic interactions between the microbiome and host cells to drive therapeutic...
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
13:36 , Mar 22, 2019 |  BC Week In Review  |  Clinical News

Aerpio's Tie2 activator fails diabetic retinopathy trial

Aerpio said twice-daily 15 mg subcutaneous AKB-9778 missed the primary endpoint in the Phase IIb TIME-2b trial to treat moderate-to-severe non-proliferative diabetic retinopathy. AKB-9778 is a tyrosine kinase receptor 2 (Tie2) activator. On the primary...
01:17 , Mar 13, 2019 |  BC Extra  |  Company News

FDA approves Aerie glaucoma therapy Rocklatan

Aerie said late Tuesday FDA approved Rocklatan netarsudil/latanoprost to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The product is a fixed-dose combination of Aerie's Rhopressa netarsudil 0.02%, a dual inhibitor of...